Phase III study to evaluate the efficacy and safety of the treatment. Two-arm, prospective, longitudinal, double-blind, multicenter randomized clinical trial.

开始日期2021-08-01

申办/合作机构

Laboratorios Silanes SA de CV

NCT04626089 / Withdrawn临床2期

Adaptive Study for Efficacy and Safety of Metformin Glycinate for the Treatment of Patients With MS and DM2, Hospitalized With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb.

The purpose of this study is to evaluate the efficacy and safety of metformin glycinate at dose of 620 mg twice per day plus standard treatment comparing to standard treatment alone (we will use placebo) of patients who have metabolic syndrome or type 2 diabetes, which have severe acute respiratory syndrome secondary to SARS-CoV-2.

开始日期2021-02-01

申办/合作机构

Laboratorios Silanes SA de CV

NCT04625985 / Completed临床2期

Adaptive Study to Demonstrate Efficacy and Safety of Metformin Glycinate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb

The purpose of this study is to evaluate the efficacy and safety of the metformin glycinate and standard treatment of the hospital in hospitalized patients with Severe Acute Respiratory Syndrome secondary to SARS-CoV2.

开始日期2020-07-14

申办/合作机构

Laboratorios Silanes SA de CV

100 项与二甲双胍甘氨酸相关的临床结果

登录后查看更多信息

100 项与二甲双胍甘氨酸相关的转化医学

登录后查看更多信息

100 项与二甲双胍甘氨酸相关的专利（医药）

登录后查看更多信息

项与二甲双胍甘氨酸相关的文献（医药）

2024-08-01·Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine

Production of iron-enriched yeast and it’s application in the treatment of iron-deficiency anemia

Article

作者: Chen, Ying ; Li, Shengshuo ; Wan, Mingli ; Zhou, Xinyi ; Liu, Xuelian ; Wan, Hongbing ; Pang, Yuanxiang

Abstract:

Iron deficiency anemia (IDA) is one of the most serious forms of malnutrition. Wild type strains of Saccharomyces cerevisiae have higher tolerance to inorganic iron and higher iron conversion and accumulation capacity. The aim of this study was to investigate the effect of S. cerevisiae enriched iron as a potential organic iron supplement on mice with iron deficiency anemia. 60 male Kunming mice (KM mice, with strong adaptability and high reproduction rate, it can be widely used in pharmacology, toxicology, microbiology and other research) were randomly divided into normal control group and iron deficiency diet model group to establish IDA model. After the model was established, IDA mice were randomly divided into 5 groups: normal control group, IDA group, organic iron group (ferrous glycinate), inorganic iron group (ferrous sulfate) and S. cerevisiae enriched iron group. Mice in the experimental group were given different kinds of iron by intragastric administration once a day for 4w. The results showed that S. cerevisiae enriched iron had an effective recovery function, and the body weight and hematological parameters of IDA mice returned to normal levels. The activities of superoxide dismutase, glutathione peroxidase and total antioxidant capacity in serum were increased. In addition, the strain no. F8, able to grow in an iron-rich environment, was more effective in alleviating IDA and improving organ indices with fewer side effects compared to ferrous glycinate and ferrous sulfate groups. This study suggests that the iron-rich strain no. F8 may play an important role in improving IDA mice and may be developed as a new iron supplement.

2024-03-01·Ecotoxicology and environmental safety

Zinc glycinate alleviates LPS-induced inflammation and intestinal barrier disruption in chicken embryos by regulating zinc homeostasis and TLR4/NF-κB pathway

Article

作者: Schroyen, Martine ; Song, Zhigang ; Xiao, Chuanpi ; Pan, Xue ; Comer, Luke ; Everaert, Nadia

The effect of an immune challenge induced by a lipopolysaccharide (LPS) exposure on systemic zinc homeostasis and the modulation of zinc glycinate (Zn-Gly) was investigated using a chicken embryo model. 160 Arbor Acres broiler fertilized eggs were randomly divided into 4 groups: CON (control group, injected with saline), LPS (LPS group, injected with 32 µg of LPS saline solution), Zn-Gly (zinc glycinate group, injected with 80 µg of zinc glycinate saline solution) and Zn-Gly+LPS (zinc glycinate and LPS group, injected with the same content of zinc glycinate and LPS saline solution). Each treatment consisted of eight replicates of five eggs each. An in ovo feeding procedure was performed at 17.5 embryonic day and samples were collected after 12 hours. The results showed that Zn-Gly attenuated the effects of LPS challenge-induced upregulation of pro-inflammatory factor interleukin 1β (IL-1β) level (P =0.003). The LPS challenge mediated zinc transporter proteins and metallothionein (MT) to regulate systemic zinc homeostasis, with increased expression of the jejunum zinc export gene zinc transporter protein 1 (ZnT-1) and elevated expression of the import genes divalent metal transporter 1 (DMT1), Zrt- and Irt-like protein 3 (Zip3), Zip8 and Zip14 (P < 0.05). A similar trend could be observed for the zinc transporter genes in the liver, which for ZnT-1 mitigated by Zn-Gly supplementation (P =0.01). Liver MT gene expression was downregulated in response to the LPS challenge (P =0.004). These alterations caused by LPS resulted in decreased serum and liver zinc levels and increased small intestinal, muscle and tibial zinc levels. Zn-Gly reversed the elevated expression of the liver zinc finger protein A20 induced by the LPS challenge (P =0.025), while Zn-Gly reduced the gene expression of the pro-inflammatory factors IL-1β and IL-6, decreased toll-like receptor 4 (TLR4) and nuclear factor kappa-B p65 (NF-κB p65) (P < 0.05). Zn-Gly also alleviated the LPS-induced downregulation of the intestinal barrier gene Claudin-1. Thus, LPS exposure prompted the mobilization of zinc transporter proteins and MT to perform the remodeling of systemic zinc homeostasis, Zn-Gly participated in the regulation of zinc homeostasis and inhibited the production of pro-inflammatory factors through the TLR4/NF-κB pathway, attenuating the inflammatory response and intestinal barrier damage caused by an immune challenge.

2024-01-01·Translational Animal Science

Determination of relative bioavailability of copper from copper glycinate in growing beef steers

Article

作者: Henderson, Jacob A ; Niedermayer-Conway, Emma K ; Hansen, Stephanie L

ABSTRACT:

Chelated copper (Cu) sources, such as Cu glycinate (CuGly), may be more bioavailable relative to Cu sulfate (CuSO4) when fed to ruminants under antagonistic pressure. The objective of this study was to determine the bioavailability of CuGly (GemStone Cu; Phibro Animal Health) relative to CuSO4 in steers fed a diet supplemented with 0.3% sulfur and 2 mg molybdenum/kg of dry matter (DM). Sixty Angus crossbred steers (n = 12 per treatment) averaging 288 ± 4.85 kg were enrolled in a 90-d study and fed a corn silage-based diet with one of five Cu supplementation strategies, including no supplemental Cu (CON), 5 or 10 mg supplemental Cu from CuSO4/kg DM, and 5 or 10 mg supplemental Cu from CuGly/kg DM. Steers were housed in pens equipped with GrowSafe feed bunks (GrowSafe Systems Ltd., Airdire, AB, Canada), with six steers per pen. Growth performance, liver Cu, and plasma Cu were analyzed in the MIXED procedure of SAS 9.4 (SAS Inst. Inc, Cary, NC) with orthogonal contrasts to compare CON vs. 5 mg Cu/kg DM, CON vs. 10 mg Cu/kg DM, 5 vs. 10 mg Cu/kg DM, and CuSO4 vs. CuGly. Copper indices were regressed against Cu intake and slopes were calculated using the GLM procedure SAS. Dietary Cu supplementation did not affect steer body weights on days 0, 28, 56, or 90 (P ≥ 0.52), average daily gain, dry matter intake, or gain:feed (P ≥ 0.36). Final plasma Cu concentration did not differ between CON vs. 5 mg Cu/kg DM (P = 0.79), CON vs. 10 mg Cu/kg DM (P = 0.65), or 5 vs. 10 mg Cu/kg DM (P = 0.39). Steers receiving CuSO4 tended to have greater final plasma Cu concentrations than those receiving CuGly (P = 0.08). Initial liver Cu concentration averaged 374 mg Cu/kg DM, which is considered highly adequate. No steers reached deficient Cu status by the end of the 90-d period. Control steers had lesser final liver Cu concentrations than supplemented steers (P ≤ 0.04). Steers receiving 10 mg supplemental Cu/kg DM had greater liver Cu concentrations than those receiving 5 mg supplemental Cu/kg DM (P = 0.01). Copper source had no effect on final liver Cu concentrations (P = 0.57) and based on liver Cu and Cu intake the bioavailability of CuGly was similar to CuSO4 (115%; P = 0.27). The initially high Cu status and the fact that cattle did not become Cu deficient may have impacted the relative bioavailability results, and more research is needed to investigate the role initial Cu status and antagonistic pressure play in the bioavailability of chelated Cu sources.

项与二甲双胍甘氨酸相关的新闻（医药）

2023-10-16

·PRNewswire

Elevating Child Mental Health: Dr. Roseann Capanna-Hodge Introduces Neurotastic™ Brain Formulas and Multi-Mag Brain™ Formula, Powered by MD Logic Health™

RIDGEFIELD, Conn., Oct. 16, 2023 /PRNewswire/ -- Pioneering child mental health expert, Dr. Roseann Capanna-Hodge, is thrilled to announce the official launch of her Neurotastic™ Brain Formulas, which include the revolutionary Multi-Mag Brain™ Formula, designed specifically to support children's mental wellbeing. Continue Reading Dr. Roseann Capanna-Hodge's Neurotastic Brain Formulas: Combining the best of science and expertise to advance children's mental health and elevate family well-being. Dr. Roseann Capanna-Hodge's podcast, "It's Gonna Be OK!" is the parenting resource for children's behavior and mental health and offers actionable, science-backed solutions that calm the brain. Having established herself as a leading authority in the realm of children's mental health through her trademarked BrainBehaviorReset™ method and founder of The Global Institute of Children's Mental Health, Dr. Roseann now extends her expertise into the world of natural supplements. Neurotastic™ Brain Formulas represent her commitment to provide science-backed, holistic solutions for improving children's and family's mental wellness. Central to the Neurotastic™ mission is the Multi-Mag Brain™ Formula, a meticulously crafted blend of the most bioavailable forms of magnesium, essential for optimal brain function. This proprietary blend combines Magnesium L-Threonate, Magnesium lysinate glycinate chelate, and di-magnesium malateS1, setting it apart in the market and ensuring maximum absorption for unparalleled mental wellness support. "Understanding the neurodivergent brain and recognizing the unique challenges children face on a daily basis, I have created resources dedicated to supporting families, organizations and the global community," Dr. Roseann remarked. "Neurotastic™ stands as a testament to our dedication to uplifting children's mental wellbeing, providing parents with the tools to help their children thrive." Magnesium's significance in mental health has been solidified through numerous research studies. We are committed to helping parents feel assured we use science based approaches, tailored specifically for the multifaceted behavioral and mental wellness needs of children. Dr. Roseann's tireless mission is to reshape the arena of children's mental health, ensuring families have access to resources anchored in science. Her vision of Neurotastic™, takes a tangible form, offering a beacon of hope to countless families. Neurotastic™ Brain Formulas at a Glance: A brainchild of a seasoned mental health expert, ensuring targeted and effective mental wellness. Custom-made to fulfill the unique mental wellbeing and behavioral needs of children and their families. An embodiment of the finest scientific advances and deep-rooted expertise, tailored for enhancing overall family well-being. Alongside her groundbreaking work, Dr. Roseann continues to share her knowledge through her books and her popular podcast, "It's Gonna be OK! The Parenting Resource for Children's Behavior and Mental Health." Her unyielding mission is to change the landscape of children's mental health, ensuring that families have access to science-backed resources and solutions. For further details on the Neurotastic™ Brain Formulas and the Multi-Mag Brain™ Formula, Powered by MD Logic Health™ and to delve into Dr. Roseann's comprehensive work in children's mental health, please visit: and . About Dr. Roseann Capanna-Hodge: Dr. Roseann is a trailblazer in children's mental health, offering a transformative approach via her BrainBehaviorReset™ method. Her decades of dedication have established her as a trusted figure in the field, guiding countless families towards a brighter, healthier future. Media Contact: Dr. Roseann Capanna-Hodge Email: [email protected] Phone: 203.438.4848 SOURCE Dr. Roseann Capanna-Hodge

100 项与二甲双胍甘氨酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	二甲双胍甘氨酸	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
高脂血症	临床3期	墨西哥	Laboratorios Silanes SA de CV	2015-10-01
2型糖尿病	临床3期	墨西哥	Laboratorios Silanes SA de CV	2014-06-01
非胰岛素依赖型糖尿病2	临床3期	墨西哥	Laboratorios Silanes SA de CV	2009-03-01
代谢综合征	临床2期	墨西哥	Laboratorios Silanes SA de CV	2021-02-01
多发性硬化症	临床2期	墨西哥	Laboratorios Silanes SA de CV	2021-02-01
肌强直性营养不良	临床2期	墨西哥	Laboratorios Silanes SA de CV	2021-02-01
新型冠状病毒感染	临床2期	墨西哥	Laboratorios Silanes SA de CV	2020-07-14
严重急性呼吸综合征	临床2期	墨西哥	Laboratorios Silanes SA de CV	2020-07-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04625985 \| NCT00940797 \| NCT04626089 (Pubmed \| Diabetes Technol Ther)	临床2期	2型糖尿病	20	Metformin Glycinate	(鹹蓋鏇淵鬱夢顧願衊遞) = 衊範鹹繭網壓觸鬱鹽鏇膚網鹹製淵網餘鹽蓋範 (鏇觸膚顧範鏇鑰襯餘顧 )	积极	2012-12-01
				Placebo	(鹹蓋鏇淵鬱夢顧願衊遞) = 製鬱顧製範憲衊鹹窪醖膚網鹹製淵網餘鹽蓋範 (鏇觸膚顧範鏇鑰襯餘顧 )